NCT04768582|Unknown
Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in Taiwanese ACS Patients
PREP-TAMI
Loading search results
PREP-TAMI
Sponsor study identifier
interventional
45
1 country
1
Study Start
May 1, 2020
Actual (reported)Primary Completion
April 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prasugrel has a faster onset of action and greater platelet inhibition with less inter-individual response variability than clopidogrel. Japan and Taiwan are the only two nations where adjusted/Asian dose of prasugrel (loading dose (LD)/maintenance (MD): 20/3.75 mg) was approved for clinical use. However, there is no data regarding the effectiveness of adjusted dose of prasugrel on platelet reactivity in Taiwanese patients with acute coronary syndrome (ACS). This study aim to evaluate the pharmacodynamic of the Asian dose prasugrel on the platelet reactivity after percutaneous coronary intervention (PCI) for patients with ACS.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 1, 2020
Actual (reported)February 18, 2021
Actual (reported)February 24, 2021
Actual (reported)April 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
platelet reactivity (PRU) after loading of prasugrel at 12 hours
PRU 12 hours after a loading dose
12 hours
platelet reactivity (PRU) after loading of prasugrel at 1 hour
one hour
platelet reactivity (PRU) after loading of prasugrel at 3 hours
3 hours
platelet reactivity (PRU) after loading of prasugrel at 48 hours
48 hours
ISTH Major bleeding
day 7 after a loading dose of prasugrel
ACS patients who received oral Prasugrel after coronary angiography been done
The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Feng Yuan Hospital
Taichung, 42055, Taiwan
CHEN RONG TSAO, M.D.
Feng Yuang Hospital
First Submitted
February 18, 2021
First Posted
February 24, 2021
Study Start
May 1, 2020
Actual (reported)Primary Completion
April 1, 2021
Estimated (date passed)PLIN1 Variants in Precocious ACS (SCAPLIN)
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 26, 2021
Record last verified: 2021-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: